Skip to main content
Caplight Logo









Ancilia Biosciences

Ancilia Biosciences

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.anciliabio.com/

Last Round

Seed

Apr 6, 2026

Total Funding Raised

$7.73M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Ancilia Biosciences is a biotechnology company developing a new class of live biotherapeutics and other microbial products with immunity to key viral pathogens by harnessing the natural power of CRISPR.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

live biotherapeuticsLBPmicrobiome therapeuticsCRISPRphage resistancebacteriophagesynthetic biologysynbiocomputational viromebioinformaticsdrug discoverymicrobial engineeringprecision medicinebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ancilia Biosciences Comparables

Compare Ancilia Biosciences with similar companies based on industry and business-model similarity.

Ancilia Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Concerto Biosciences
71%
Eligo Bioscience
71%
Vedanta Biosciences
67%

Ancilia Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 6, 2026
GrantOct 23, 2024
GrantOct 23, 2024
SeedJul 17, 2024
GrantAug 1, 2021

Key People

Founding team and executive leadership

David Páez-Espino

Chief Technology Officer, Co-Founder

Founding Team

Alexandra Sakatos

Co-Founder CEO

Founding Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 464% MoM, from 286 to 1.6K.

  • Apr 6, 2026

    $10M Seed Round raised.

Ancilia Biosciences Filings

Explore SEC and related filing metadata, where available.

Ancilia Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Ancilia Biosciences's valuation, stock price, and market status.

Is Ancilia Biosciences a public or private company?

Ancilia Biosciences is a private company.

What is the current stock price of Ancilia Biosciences?

Ancilia Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is Ancilia Biosciences worth (valuation)?

Valuation information for Ancilia Biosciences is not publicly available.

Can I buy Ancilia Biosciences stock?

Ancilia Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Ancilia Biosciences's last funding round?

Ancilia Biosciences's most recent funding round was Seed Round on April 6, 2026.

Who are the main investors in Ancilia Biosciences?

Key investors in Ancilia Biosciences include Safar Partners.

Will Ancilia Biosciences IPO soon?

No public IPO plans have been announced for Ancilia Biosciences.

How can I track Ancilia Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ancilia Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Employee Range19
Year Founded2019
Last FundingApr 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?